Richard J. Lim Net Worth

The estimated Net Worth of Richard J. Lim is at least 2.65 百万$ dollars as of 27 June 2016. Richard Lim owns over 461,538 units of Paratek Pharmaceuticals stock worth over 2,647,824$ and over the last 10 years Richard sold PRTK stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Lim PRTK stock SEC Form 4 insiders trading

Richard has made over 1 trades of the Paratek Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Richard bought 461,538 units of PRTK stock worth 5,999,994$ on 27 June 2016.

The largest trade Richard's ever made was buying 461,538 units of Paratek Pharmaceuticals stock on 27 June 2016 worth over 5,999,994$. On average, Richard trades about 230,769 units every 0 days since 2014. As of 27 June 2016 Richard still owns at least 1,187,365 units of Paratek Pharmaceuticals stock.

You can see the complete history of Richard Lim stock trades at the bottom of the page.

What's Richard Lim's mailing address?

Richard's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON, MA, 02111.

Insiders trading at Paratek Pharmaceuticals

Over the last 10 years, insiders at Paratek Pharmaceuticals have traded over 9,410,794$ worth of Paratek Pharmaceuticals stock and bought 1,743,576 units worth 13,751,429$ . The most active insiders traders include James D Dondero、Bioventures Cayman Ltd Hbm、Evan Loh. On average, Paratek Pharmaceuticals executives and independent directors trade stock every 24 days with the average trade being worth of 63,310$. The most recent stock trade was executed by Randall B. Brenner on 8 August 2023, trading 27,603 units of PRTK stock currently worth 60,727$.

What does Paratek Pharmaceuticals do?

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.

Complete history of Richard Lim stock trades at Paratek Pharmaceuticals

Paratek Pharmaceuticals executives and stock owners

Paratek Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Evan Loh FACC, FAHA, M.D.,
  CEO & Director
• Dr. Evan Loh,
  CEO & Director
• Michael F. Bigham CPA, CPA, M.B.A., MBA,
  Exec. Chairman
• Michael F. Bigham CPA, M.B.A., CPA, MBA,
  Exec. Chairman
• Adam Woodrow,
  Pres & Chief Commercial Officer
• Leonid Sevastyanov,
  Independent Director
• Sergey Guz,
  Independent Director
• Aleksandr Sukhoruchenko,
  Director
• Vadim Gorbunov,
  Director
• Yuliya Yakunina,
  Director, Director of Economics
• Timofey Prokopov,
  Vice President for Finance and Investment
• Anna Kinash,
  Chief Accountant
• Vadim Muzyaev,
  President, Deputy Chairman of the Board
• Vadim Yakunin,
  Chairman of the Board, Adviser to President
• Randall B. Brenner,
  Chief Devel. & Regulatory Officer
• Karen McGrath,
  Sr. VP of HR
• Christine R. Coyne M.B.A.,
  VP of Marketing
• Ben Strain,
  VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
• Jason Burdette,
  Sr. VP of Technical Operations
• Sarah Higgins,
  VP, Controller and Interim Principal Financial & Accounting Officer
• William M. Haskel,
  Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Michael Bigham,
  Exec. Chairman of the Board
• Fund Iii, L.P.Omega Fund Iv...,
  
• Douglas W. Pagan,
  Chief Financial Officer
• Thomas John Dietz,
  Director
• Robert S Radie,
  Director
• Richard J. Lim,
  Director
• Timothy R Franson,
  Director
• Jeffrey Stein,
  Director
• Kristine Peterson,
  Director
• William M. Haskel,
  CLO, General Counsel & Sec.
• Evan Loh,
  CEO
• Randall B. Brenner,
  Chief Development & Regulatory
• Kathryn M. Boxmeyer,
  See Remarks
• Bioventures Cayman Ltd Hbm,
  10% owner
• Rolf K Hoffmann,
  Director
• Minnie Baylor Henry,
  Director
• James D Dondero,
  10% owner